Drug Profile
Research programme: neurological disorders therapeutics - KineMed
Alternative Names: Cognition disorders programme - KineMed; KM-801; Neurodegenerative disorders programme - KineMedLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator KineMed
- Class Small molecules
- Mechanism of Action Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Cognition disorders; Neurodegenerative disorders; Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA